Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus
NEW YORK, Jan 3, 2026, 20:43 ET — Market closed Kymera Therapeutics shares slid on Friday, ending down 6.6% at $72.76 as the biotech underperformed its sector even as the broader market started 2026 on a mixed note. The move matters because Kymera has been a high-beta biotech name since a sharp rally in December on early trial data for its KT-621 immunology program, leaving the stock sensitive to profit-taking and fresh supply from capital-raising activity. Kymeratx With U.S. markets facing a busy week of economic releases, risk appetite has been uneven and investors have leaned on near-term catalysts —